22157.jpg
The Psychedelic Drugs Market - Global Industry Analysis (2018-2020), Growth Trends, and Market Forecast (2021-2026)
October 04, 2021 04:33 ET | Research and Markets
Dublin, Oct. 04, 2021 (GLOBE NEWSWIRE) -- The "Psychedelic Drugs Market - Global Industry Analysis (2018-2020) - Growth Trends and Market Forecast (2021-2026)" report has been added to...
Picture1.jpg
Clearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
October 01, 2021 08:00 ET | Clearmind Medicine
TORONTO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and...
trypf.png
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Redefining Standards, Refining Psychiatry
September 28, 2021 08:30 ET | Tryp Therapeutics Inc.
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
Palo Santo is a U.S.-based psychedelic investment fund focused on increasing the supply of clinically effective and accessible mental health and addiction treatment solutions needed in today’s world.
U.S.-Based Psychedelic Healthcare VC Fund, Palo Santo, Announces Recent Investment in neurocare Group
September 21, 2021 08:51 ET | Palo Santo
CHICAGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Palo Santo, a U.S.-based psychedelic investment fund, announced its recent investment in neurocare Group AG (“neurocare”), a leading provider of...
Picture1.jpg
Clearmind Medicine Partners with The Hebrew University to Develop Novel Psychedelic Drug
September 21, 2021 07:00 ET | Clearmind Medicine
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery...
psychable.png
This Magic Mushroom Day, Communities Across the Globe Celebrate the Transformative Healing Power of Using Psychedelics as Medicine
September 20, 2021 08:30 ET | Psychable, Inc.
LOS ANGELES, Sept. 20, 2021 (GLOBE NEWSWIRE) -- September 20 is Magic Mushroom Day and this year, communities across the world are celebrating the psychedelic renaissance. As research, clinical...
psychable.png
Pain Awareness Month: Psychable Educates Patients on Transformative Power of Using Psychedelics as Medicine for Pain Treatment, Management and Healing
September 15, 2021 20:30 ET | Psychable, Inc.
LOS ANGELES, Sept. 15, 2021 (GLOBE NEWSWIRE) -- September is Pain Awareness Month. Affecting more than 50 million Americans, chronic pain - both unmanaged and unmanaged, physical and emotional - is...
NEW ATAI-Logo_Primary.png
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
September 15, 2021 08:10 ET | atai Life Sciences
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
NEW ATAI-Logo_Primary.png
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
September 14, 2021 08:00 ET | atai Life Sciences
NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in...
NEW ATAI-Logo_Primary.png
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
September 09, 2021 16:30 ET | atai Life Sciences
BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...